Contact this trialFirst, we need to learn more about you.
NNC6019-0001 for Transthyretin Amyloid Cardiomyopathy
Recruiting0 awardsPhase 2
Portland, Oregon
This trial is testing a new potential medicine, NNC6019-0001, for heart disease caused by TTR amyloidosis. The study will look at if this medicine can reduce symptoms of heart failure associated with the disease. Participants will be randomly assigned to receive either the new medicine or a placebo, and the study will last about 64 weeks.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.